Autologous Bone Marrow Transplantation - Blog Science Connections

More documents

Recommendations

Info

Contents Preface xix Acknowledgments xxi Session I - Leukemia A. CLINICAL STÜDES IN FIRSTREMISSION LEUKEMIA Autologous Bone Marrow Transplantation in Patients With Acute Myeloid Leukemia in First Remission 3 B. Lowenberg, J. van der Lelie, R. Goudsmit, R. Willemze, F. E. Zwaan, A. Hagenbeek, W. J. L. van Putten, L. F. Verdonck, and Q. C. de Gast BA VC Regimen and Autologous Bone Marrow Transplantation in Patients With Acute Myelogenous Leukemia in Remission 9 Giovanna Meloni, Paolo de Fabritiis, Alessandro Pulsoni, Antonella Sandrelli, Francesco Malagnino, Maria Concetta Petti, Alfredo Covelli, and Franco Mandelli Use of Bone Marrow Incubated With Mafosfamide in Adult Acute Leukemia Patients in Remission: The Experience of the Paris Saint- Antoine Transplant Team 15 N. C. Gorin, J. P. Laporte, L. Douay, M. Lopez, J. Stachowiak, P. Aegerter, J. Deloux, J. L. Marin, G. Duhamel, A. Laugier, Ch. Salmon, and A. Najman Autologous Transplantation of Unpurged Bone Marrow During First Remission of Acute Myeloid Leukemia 23 Alan K. Burnett, Stephen Mackinnon, and Ann Morrison Autologous Bone Marrow Transplantation for Acute Myelogenous Leukemia: 24 Unselected Patients in First Remission 31 J.-Y. Cahn, M. Flesch, E. Plouvier, B. Pignon, C. Behar, B. Audhuy, A. Boilletot, P. Lutz, A. Noir, and P. Herve oil
Page 1: Autologous Bone Marrow Transplantat
Page 5 and 6: Autologous Bone Marrow Transplantat
Page 7: To our colleagues, Drs. R. Lee Clar
Page 11 and 12: ABMT ix Double Unpurged Autologous
Page 13 and 14: ABMT xi Treating Advanced Hodgkin's
Page 15 and 16: ABMT xiii Repeated High-Dose Chemot
Page 17 and 18: ABMT xu Session V - Lung Cancer Det
Page 19 and 20: ABMT xuii Toxic Deaths After Autolo
Page 21: Preface The Proceedings of the Thir
Page 25: IA. Clinical Studies in First-Remis
Page 28 and 29: 4 AML in First Remission used in pa
Page 30 and 31: 6 AML in First Remission i 40- < 3
Page 33 and 34: BAVC Regimen and Autologous Bone Ma
Page 35 and 36: BAVC + ABMT in Patients With AML in
Page 37 and 38: BAVC + ABMT in Patients With AML in
Page 39 and 40: Use of Bone Marrow Incubated With M
Page 41 and 42: Purged ABMT in CR of Acute Leukemia
Page 47 and 48: Autologous Transplantation of Unpur
Page 49 and 50: First-Remission Autograft forAML 25
Page 51 and 52: s o CO s •o « k. 3 Q. P CO l_ O
Page 53: First-Remission Autograft for AML 2
Page 56 and 57: 32 Transplantation in CRI AML Of 24
Page 59 and 60:
Autologous Bone Marrow Transplantat
Page 61 and 62:
ABMT in ALL 37 Table 1. Patient Cha
Page 63 and 64:
ABMT in ALL 39 CRj (N. 16) CRJ+CRJ
Page 65 and 66:
ABMT in ALL 41 (46.5% for ALL and 4
Page 67 and 68:
Studies of High-Dose Intensificatio
Page 69 and 70:
ABMTinCRl 45 Induction V A D C- V A
Page 71:
ABMTin CRI 47 DFS rate for the CBV-
Page 74 and 75:
50 Panel Discussion: Session IA the
Page 76 and 77:
52 Panel Discussion: Session IA DR.
Page 79 and 80:
A Study Design to Determine the Rol
Page 81 and 82:
ABMT In CR2 57 CR INVERSION: 2/22 -
Page 83 and 84:
Page 85 and 86:
ABMT in Acute Nonlymphocytic Leukem
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Transplantation Trial With Marrow T
Page 95 and 96:
ABMTin AML With Monoclonal Antibodi
Page 97 and 98:
ABMT in AML With Monoclonal Antibod
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Chemopurging of Autologous Bone Mar
Page 105 and 106:
Mafosfamlde Purging in Leukemia 81
Page 107 and 108:
Mafosfamide Purging in Leukemia 83
Page 109 and 110:
Page 111:
Page 114 and 115:
90 ABMT in CR2 Pediatric ALL Immuno
Page 116 and 117:
92 ABMT in CR2 Pediatric ALL first
Page 118 and 119:
94 Ex Vivo Marrow Purging with marr
Page 120 and 121:
96 Ex Vivo Marrow Purging BONE MARR
Page 122 and 123:
98 Ex Vivo Marrow Purging reflect t
Page 124 and 125:
700 Conditioning Regimens in AML cy
Page 126 and 127:
102 Conditioning Regimens in AML Ta
Page 129 and 130:
Double CInpurged Autologous Bone Ma
Page 131 and 132:
Double Unpurged ABMT in Leukemias 1
Page 133 and 134:
Double (Jnpurged ABMT in Leukemias
Page 135 and 136:
Double Autografting as Potential Cu
Page 137 and 138:
Double Autografting in Acute Leukem
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Hematopoietic Recovery After Bone M
Page 145 and 146:
Recovery After 4-Hydroperoxycycloph
Page 147:
Recovery After 4-Hydroperoxycycloph
Page 150 and 151:
126 Panel Discussion: Session IB DR
Page 152 and 153:
128 Panel Discussion: Session IB 18
Page 155:
IC. Leukemia Purging/Detection of M
Page 158 and 159:
134 Magnetic Separation of Marrow C
Page 160 and 161:
Page 162 and 163:
Ol O) < c « .o. >» o T3 c « =5
Page 164 and 165:
M I M ! CM CO CO CO CO LO M M CO CO
Page 166 and 167:
Page 168 and 169:
144 Chemopurging leukemic (ALL) pat
Page 170 and 171:
746 Chemopurging isoeffect. On the
Page 172 and 173:
148 Chemopurging Table 4. Ex Vivo P
Page 174 and 175:
750 Chemopurging 5. Kaizer H, Stuar
Page 176 and 177:
152 Merocyanine 540 Marrow Decontam
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
758 CALLA-Negatiue Clonogenic B-Cel
Page 184 and 185:
160 CALLA-Negatiue Clonogenic B-Cel
Page 187 and 188:
Acetaldophosphamide—A New Stable
Page 189 and 190:
Acetaldophosphamide Ex Vivo Chemoth
Page 191 and 192:
Page 193:
Page 196 and 197:
172 Detecting Residual Disease in B
Page 198 and 199:
174 Detecting Residual Disease in B
Page 201 and 202:
Pharmacological Manipulation to Rev
Page 203 and 204:
Pharmacological Manipulation and Pu
Page 205 and 206:
Page 207 and 208:
Page 209:
Page 213 and 214:
Transient Restoration of Partial Ph
Page 215 and 216:
CO o o o o o •o c co CD È >•!
Page 217 and 218:
CML Chronic Phase Autografting 193
Page 219 and 220:
Mitoxantrone, Cytarabine, and Melph
Page 221:
CML Blast Crisis Autografting 197 c
Page 224 and 225:
200 Autografting in Chronic Granulo
Page 226 and 227:
202 Autografting in Chronic Granulo
Page 229 and 230:
Page 231:
IIA. Hodgkin's Disease
Page 234 and 235:
210 ABMTin Hodgkin's Disease Analys
Page 236 and 237:
212 ABMTin Hodgkin's Disease CR n =
Page 238 and 239:
214 ABMTin Hodgkin's Disease Postmo
Page 240 and 241:
216 ABMTin Hodgkin's Disease progno
Page 242 and 243:
218 CBV and ABMT in Hodgkin s Disea
Page 244 and 245:
220 CBV and ABMT in Hodgkin s Disea
Page 247 and 248:
High-Dose Chemotherapy and Autologo
Page 249 and 250:
Chemotherapy andABMT in Hodgkin's D
Page 251 and 252:
Chemotherapy and ABMTin Hodgkin's D
Page 253 and 254:
Chemotherapy andABMTin Hodgkin s Di
Page 255 and 256:
Treating Advanced Hodgkin's Disease
Page 257 and 258:
ABMT for Advanced Hodgkin's Disease
Page 259:
ABMT for Advanced Hodgkin's Disease
Page 262 and 263:
238 Panel Discussion: Session IIA D
Page 264 and 265:
240 Panel Discussion: Session IIA D
Page 267 and 268:
Recent Results With Salvage Chemoth
Page 269 and 270:
Salvage Chemotherapy for Lymphoma 2
Page 271:
Salvage Chemotherapy for Lymphoma 2
Page 274 and 275:
250 ABMTin Burkitt's Lymphoma (8-10
Page 276 and 277:
252 ABMT in Burkitt's Lymphoma intr
Page 278 and 279:
254 ABMTin Burkitts Lymphoma Table
Page 280 and 281:
256 ABMT in Burkitt's Lymphoma rela
Page 282 and 283:
258 ABMT in Burkitt's Lymphoma DISC
Page 284 and 285:
260 ABMTin Burkitts Lymphoma restri
Page 287 and 288:
Biology and Therapy of Multiple Mye
Page 289 and 290:
Myeloma Biology and Therapy 265 onl
Page 291 and 292:
Myeloma Biology and Therapy 267 res
Page 293 and 294:
Bone Marrow Transplantation in Rela
Page 295 and 296:
(S E o I 9*1 0 ü 41 O) CD ~ i: O)
Page 297 and 298:
BMT in Relapsed Diffuse Large Cell
Page 299 and 300:
Treatment of Malignant Lymphoma at
Page 301:
Transplantation for Malignant Lymph
Page 304 and 305:
280 ABMT Timing in Lymphoma produce
Page 306 and 307:
0) O) .2 '55 o c O) o o Q. c o + +
Page 308 and 309:
284 ABMT Timing in Lymphoma ABMT on
Page 310 and 311:
286 ABMT Timing in Lymphoma abdomin
Page 312 and 313:
« "5 a o « £ a> Z aT in O Q « O
Page 314 and 315:
290 ABMT Timing in Lymphoma Role of
Page 316 and 317:
292 ABMT Timing in Lymphoma inducti
Page 318 and 319:
294 ABMT Timing in Lymphoma Clift R
Page 321 and 322:
Treatment Strategies for Advanced A
Page 323 and 324:
Treatment Strategies for NHL 299 Su
Page 325 and 326:
« E BS « oc c 4> E ai O c CD e 0)
Page 327 and 328:
Treatment Strategies for NHL 303 So
Page 329 and 330:
Treatment Strategies for NHL 305 pa
Page 331 and 332:
Non-Hodgkin's Lymphoma S. Gulati an
Page 333:
Panel Discussion: Session IIB 309 i
Page 337 and 338:
An International Randomized Study o
Page 339 and 340:
Proposed International Adult Lympho
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357:
Page 360 and 361:
336 International NHL Trial THEORET
Page 362 and 363:
338 International NHL Trial RELAPSE
Page 364 and 365:
340 International NHL Trial ANALYSI
Page 366 and 367:
342 International NHL Trial The ste
Page 368 and 369:
344 Panel Discussion: Session IIC d
Page 371 and 372:
Chemoimmunoseparation of T Lymphoma
Page 373 and 374:
Chemoimmunoseparation of T Lymphoma
Page 375 and 376:
Using a Liquid Cell Culture Assay t
Page 377 and 378:
Burkitt's Lymphoma Purging Assay 35
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Comparative Efficiency of an Immuno
Page 385 and 386:
Purging Methods in Burkitt's Lympho
Page 387 and 388:
Purging Methods in Burkitt's Lympho
Page 389 and 390:
Susceptibility of Lymphoid Malignan
Page 391 and 392:
Leukemia Cell Sensitioity to Immuno
Page 393 and 394:
Leukemia Cell Sensitivity to Immuno
Page 395 and 396:
Lymphoma: Purging and Detecting K.
Page 397:
III. Neuroblastoma
Page 400 and 401:
376 ABMT for Neuroblastoma TOXICITY
Page 402 and 403:
378 ABMT for Neuroblastoma 100 Befo
Page 404 and 405:
380 ABMTfor Neuroblastoma modificat
Page 406 and 407:
382 ABMTfor Neuroblastoma Naval Med
Page 408 and 409:
384 ABMT in Metastatic Neuroblastom
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 417 and 418:
High-Dose Therapy and Unpurged Bone
Page 419 and 420:
Unpurged ABMTfor Neuroblastoma 395
Page 421 and 422:
(Jnpurged ABMT for Neuroblastoma 39
Page 423:
Unpurged ABMT for Neuroblastoma 399
Page 426 and 427:
402 High-Dose Melphalan in Neurobla
Page 428 and 429:
404 High-Dose Melphalan in Neurobla
Page 431 and 432:
Bone Marrow Transplantation in an C
Page 433 and 434:
ABMT in 65 Patients With Neuroblast
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
ABMTin 65 Patients With Neuroblasto
Page 441:
ABMTin 65 Patients With Neuroblasto
Page 444 and 445:
420 ABMT in Neuroblastoma Group 2
Page 446 and 447:
422 ABMT in Neuroblastoma RESULTS A
Page 449 and 450:
Transplantation for Neuroblastoma U
Page 451 and 452:
Purged Marrow Engraftment in Neurob
Page 453 and 454:
Page 455:
Page 458 and 459:
s o o o i o i - w n . t t i s T - T
Page 460 and 461:
436 Digital Image Analysis System a
Page 462 and 463:
438 Digital Image Analysis System T
Page 464 and 465:
440 Digital Image Analysis System u
Page 467 and 468:
Eliminating Burkitt's Cells From Ex
Page 469 and 470:
Immunomagnetic Purging ofBurkitt's
Page 471 and 472:
Immunomagnetic Purging ofBurkitt's
Page 473 and 474:
Neuroblastoma T. Philip and C. P. R
Page 475 and 476:
Panel Discussion: Session 111 451 w
Page 477:
IV. Breast Cancer
Page 480 and 481:
456 High-Dose Chemotherapy and ABMT
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 489 and 490:
Strategies in the Treatment of Brea
Page 491 and 492:
Treatment Strategies in Breast Canc
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Phase I and II Studies of High-Dose
Page 501 and 502:
a « O 75 o c Ü co s g c .2 — o
Page 503 and 504:
+ O CM CD CM CO CO O O CM O CM CM 8
Page 505 and 506:
High-Dose Chemotherapy and Autologo
Page 507 and 508:
High-Dose Therapy and ABMT in Breas
Page 509 and 510:
Immunodetection of Breast Carcinoma
Page 511:
Immunodetection of Breast Carcinoma
Page 514 and 515:
490 ABMTfor Breast Cancer initial s
Page 516 and 517:
492 ABMT for Breast Cancer agent gr
Page 518 and 519:
494 ABMT for Breast Cancer approach
Page 521 and 522:
Detection of Occult Breast Cancer C
Page 523 and 524:
Occult Breast Cancer Cells in Marro
Page 525 and 526:
Occult Breast Cancer Cells in Marro
Page 527 and 528:
Breast Cancer E. Frei III and R. Ba
Page 529 and 530:
Panel Discussion: Session IV 505 DR
Page 531:
V. Lung Cancer
Page 534 and 535:
570 Tumor Cell Detection MATERIAL A
Page 536 and 537:
512 Tumor Cell Detection Table 3. I
Page 539 and 540:
High-Dose Etoposide and Cisplatin W
Page 541 and 542:
Etoposide and Cisplatin for Lung Ca
Page 543 and 544:
Page 545:
Page 548 and 549:
524 Panel Discussion: Session V to
Page 550 and 551:
526 Panel Discussion: Session V sma
Page 553:
VI. Melanoma/Sarcoma/Carcinoma
Page 556 and 557:
532 ABMT in Melanoma chemotherapy a
Page 558 and 559:
534 ABMT in Melanoma Table 2. Effec
Page 560 and 561:
536 ABMT in Melanoma with either si
Page 562 and 563:
538 Panel Discussion: Session VI ca
Page 564 and 565:
540 Panel Discussion: Session VI sa
Page 567 and 568:
Intensive Monochemotherapy With Car
Page 569 and 570:
Carmustine and ABMTfor Malignant Gl
Page 571:
Carmustine andABMTfor Malignant Gli
Page 574 and 575:
550 High-Dose Carmustine and Transp
Page 576 and 577:
Page 578 and 579:
Page 580 and 581:
Page 582 and 583:
558 High-Dose Therapy of CHS Glioma
Page 584 and 585:
Page 586 and 587:
Page 589 and 590:
Brain Cancer S. Wolff and G. Herzig
Page 591:
Panel Discussion: Session VII 567 D
Page 595 and 596:
Intensification Regimens for Autolo
Page 597 and 598:
Clinical Intensification Regimens f
Page 599 and 600:
c « O) o in CM -r 1 •«t 00 i -
Page 601 and 602:
Page 603:
Page 606 and 607:
582 Busulfan + Cyclophosphamide in
Page 608 and 609:
Busulfan + Cyclophosphamide in Chil
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
590 Intensive use of Carmustine Pul
Page 617 and 618:
A Phase II Study of a New Cytoreduc
Page 619 and 620:
BEAM: Cytoreductiue Regimen for Lym
Page 621 and 622:
BEAM: Cytoreductiue Regimen for Lym
Page 623 and 624:
BEAM: Cytoreductlue Regimen for Lym
Page 625 and 626:
Total Body Irradiation, High-Dose C
Page 627 and 628:
Total Body Irradiation, Cytarabine,
Page 629 and 630:
New Regimens K. Antman and M. Syman
Page 631:
IX. Supportive Therapy
Page 634 and 635:
670 Herpesvirus Infections Table 1.
Page 636 and 637:
612 Herpesvirus Infections Table 3.
Page 639 and 640:
Autologous Blood Stem Cell Transpla
Page 641 and 642:
Peripheral Stem Cell Transplantatio
Page 643 and 644:
Page 645 and 646:
Page 647 and 648:
Page 649 and 650:
a c CO TO O O S E => CO "O CO i- t
Page 651 and 652:
3 w •o « C C o ü ü CD < , o E
Page 653 and 654:
Page 655 and 656:
Page 657 and 658:
Toxic Deaths After Autologous Bone
Page 659 and 660:
Toxic Deaths in ABMT 635 RESULTS Fi
Page 661 and 662:
Toxic Deaths in ABMT 63 7 Patient/
Page 663 and 664:
Infectious Complications of Autolog
Page 665 and 666:
Infectious Complications of ABMT Ta
Page 667 and 668:
Infectious Complications ofABMT 643
Page 669:
Infectious Complications ofABMT 645
Page 672 and 673:
648 Infections in ABMT MATERIAL AND
Page 674 and 675:
650 Infections in ABMT Category Tab
Page 676 and 677:
652 Infections in ABMT been found,
Page 678 and 679:
654 Antibiotics in Cancer Patients
Page 680 and 681:
656 Antibiotics in Cancer Patients
Page 683 and 684:
The Empiric Use of Amphotericin B f
Page 685 and 686:
Amphotericin B for Neutropenie Feue
Page 687 and 688:
Amphotericin B for Neutropenie Feve
Page 689 and 690:
The Role of Intravenous Immune Glob
Page 691 and 692:
Mg in ABMT 667 broken down; antigen
Page 693 and 694:
The Possible Therapeutic Value of N
Page 695 and 696:
Natural Killer Cells and Transplant
Page 697:
Natural Killer Cells and Transplant
Page 700:
676 Transplantation of Circulating
Page 703:
Transplantation of Circulating Stem
Page 706 and 707:
682 Peripheral Stem Cell Transplant
Page 708 and 709:
684 Peripheral Stem Cell Transplant
Page 711 and 712:
Autologous Transplantation Using Pe
Page 713 and 714:
Peripheral Blood Stem Cell Transpla
Page 715 and 716:
Peripheral Blood Stem Cell Transpla
Page 717 and 718:
Bronchoscopic Examination and Bronc
Page 719 and 720:
Bronchoscopy in Marrow Transplantat
Page 721 and 722:
Effect of Interleukin 2 on T Lympho
Page 723 and 724:
c c 4) "5 Q. Ss •o 3 35 (A U «5
Page 725 and 726:
T Lymphocyte CFU After ABMT 701 Six
Page 727:
T Lymphocyte CFCJ After ABMT 703 no
Page 730 and 731:
706 Panel Discussion: Session IX se
Page 733 and 734:
Expression of Human Adenosine Deami
Page 735 and 736:
Human ADA in Monkeys 711 to the SAX
Page 737 and 738:
Human ADA in Monkeys 713 4 were nev
Page 739 and 740:
Human ADA in Monkeys 715 tuted marr
Page 741 and 742:
Electric Field-Mediated DNA Transfe
Page 743 and 744:
Page 745:
Page 748 and 749:
724 Aberrant Gene Expression in AML
Page 750 and 751:
Page 752 and 753:
Page 755 and 756:
Clonal Detection of Remission by Re
Page 757 and 758:
Clonal Detection of Remission 733 c
Page 759 and 760:
Clonal Detection of Remission 3 735
Page 761:
XI. Summary
Page 764 and 765:
740 Summary administration of the a
Page 766 and 767:
742 Summary particularly apparent i
Page 768 and 769:
744 Summary limited occurrence of t
Page 771 and 772:
Concluding Remarks Karel A. Dicke I
Page 773 and 774:
Contributors and Participants Zora
Page 775 and 776:
Contributors and Participants 751 M
Page 777 and 778:
Contributors and Participants 753 A
Page 779 and 780:
Contributors and Participants 755 R
Page 781 and 782:
Contributors and Participants 757 M
Page 783 and 784:
Contributors and Participants Leona
Page 785 and 786:
Contributors and Participants 761 L
Page 787 and 788:
Contributors and Participants 763 B
Page 789 and 790:
Contributors and Participants 765 J
Page 791 and 792:
Page 793 and 794:
Contributors and Participants 769 B
Page 795 and 796:
Contributors and Participants 771 G
Page 797 and 798:
Contributors and Participants 773 A
Page 799 and 800:
show all

Autologous Bone Marrow Transplantation - Blog Science Connections

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?